ALL

Question 1

Immunophenotype: B-cell

Answer 1

CD19, CD20, CD79a, cytoplasmic CD22, PAX5

CD3- (T-cell)

Question 2

Myeloid Ag that rules out B-ALL/LBL

Answer 2

MPO

Question 3

Immunophenotype: Hairy cell leuk

Answer 3

CD11c+, CD103+

Question 4

Immunophenotype: blasts

Answer 4

CD34+, CD117+, CD123+, HLA-DR+

Question 5

Immunophenotype: myeloid lineage (AML)

Answer 5

CD13, CD33, MPO, CD11b

Question 6

Immunophenotype: T-cell

Answer 6

CD2, CD3, CD5, CD7, CD30

Question 7

Immunophenotype: common leukocyte

Answer 7

CD45

Question 8

ALL poor risk cytogenetics

Answer 8

hypodiploid
KMT2A rearranged t[4;11]
t(v;14q32)/IgH
t(17;19)
T(9;22)
complex karyotype
BCR-ABL1-like (JAK-STAT, ABL class)
C21 amplification
IKZF1 alterations

Question 9

Tx: MRD+ following ALL induction?

Answer 9

Blinatumomab followed by HCT

Question 10

Favorable cytogenetics in ALL?

Answer 10

hyperdiploidy, t(12;21), ETV6-RUNX1

Question 11

HSCT late phase (>100days) complications?

Answer 11

Aspergillus, PJP, encapsulated bacteria, VZV

Question 12

HSCT post-engraftment phase (30-100days) complications?

Answer 12

CMV, PJP, aspergillus

Question 13

HSCT pre-engraftment phase (<30 days) complications?

Answer 13

HSV, G +/- bacteria, candida/aspergillus – from neutropenia

Question 14

Significant complication of cyclosporine or tacrolimus

Answer 14

TMA (thrombotic microangiopathy) with hemolytic anemia

Question 15

Stage IV Acute GVHD criteria?

Answer 15

Skin: erythema >50% BSA with bullous/desquamation >5% BSA
Liver: bili>15
Lower GI: severe abdominal pain with or without ileus or grossly bloody stool

Question 16

Ph-like ALL treatment for ABL1, ABL2, CSF1R and PDGFRB fusions?

Answer 16

dasatinib

Question 17

ALL with JAK-STAT, ABL fusions, PDGRF, NTRK, FLT3 mutations is called?

Answer 17

Ph-like (BCR-ABL1 like) ALL

Question 18

MRD level detected by 6-color flow cytometry to predict relapse in ALL after HSCT?

Answer 18

<1 x 10^-4 (threshold for flow) or <0.01%

Question 19

MRD level detected by PCR/NGS for leukemic cells?

Answer 19

<1 x 10^-6 or <0.0001%

Question 20

Blinatumumab MOA?

Answer 20

Connector between CD19 on (B-cell leukemic cells) and CD3 (on T-cell lymphocytes)

Question 21

Tx for ALL relapse in CNS or testes?

Answer 21

systemic therapy (chemo, bilatumomab, inotuzumab ozo, CAR-T with Tisa or Brex)

Question 22

blackbox warning for inotuzumab ozogamicin?

Answer 22

veno-occlusive liver disease

Question 23

what is the % of hemosiderin laden macrophages among all alveolar macrophages (from BAL) to help confirm dx of Diffuse Alveolar Hemorrhage (DAH)?

Answer 23

20%

Question 24

How long do you continue TKI in Ph+ ALL after HSCT?

Answer 24

1 year

Question 25

Large Granular Lymphocytic (LGL) leukemia is divided into which 2 groups?

Answer 25

1. T-cell LGL leukemia
2. NK cell LGL leukemia

Question 26

T-LGL associations?

Answer 26

Rheum arthritis, splenomegaly, anemia, neutropenia

Question 27

Substitution for pegaspargase in ALL regimens?

Answer 27

can use calaspargase (Cal-PEG) in pt <21yo for mor sustained activity

Question 28

Risk factor to develop pure red cell aplasia following HSCT?

Answer 28

use of fludarabine/busulfan conditioning regimen

Question 29

MC mutation in hypodiploid ALL?

Answer 29

TP53